姜黄素 (Cur) 是一种广泛使用的来自癌症患者的补充衍生药物。制备来自 82 名患者的球状体样本，并在 48 小时后用两种 Cur 制剂（CurA、CurB）进行单一和联合治疗。 72小时后，评估细胞活力和形态。 Cur 配方具有显着的抑制效果，为 -8.47% (p < 0.001)，CurA 为 -10.01% (-50.14-23.11%，p = 0.001)，CurB 为 -6.30% (-33.50-19.30%，p = 0.006)。 ，与其溶剂对照聚乙二醇、β-环糊精 (CurA) 和 Kolliphor-ELP、柠檬酸盐 (CurB) 相比。 Cur 制剂对前列腺癌 (-19.54%) 更有效，对妇科非乳腺癌 (0.30%) 效果较差。 CurA 在年龄 <40 岁 (-13.81%) 和 >70 岁 (-17.74%) 的患者样本中显示出更好的反应。 CurB 对转移性和经过大量预处理的肿瘤具有更强的作用。 Cur 制剂和标准疗法的组合在 20/47 样本 (42.55%) 中优于，在 7/47 (14.89%) 中较差。 CurB 比单一疗法对化疗双药的刺激更强烈（-0.53% vs. -6.51%，p = 0.022），并且比 CurA 更有效（-6.51% vs. 3.33%，p = 0.005）。 Cur 制剂与青蒿琥酯、白藜芦醇和维生素 C 的组合在 35/70 (50.00%) 的样品中优于，在 16/70 (22.86%) 的样品中较差。与青蒿琥酯联合使用可显着增强 Cur 配方的效果 (p = 0.020)。 Cur 制剂的抗癌效果存在很大差异，这表明在给药前需要进行个体测试。

Curcumin (Cur) is a heavily used complementary derived drug from cancer patients. Spheroid samples derived from 82 patients were prepared and treated after 48 h with two Cur formulations (CurA, CurB) in mono- and combination therapy. After 72 h, cell viability and morphology were assessed. The Cur formulations had significant inhibitory effects of -8.47% (p < 0.001), CurA of -10.01% (-50.14-23.11%, p = 0.001) and CurB of -6.30% (-33.50-19.30%, p = 0.006), compared to their solvent controls Polyethylene-glycol, β-Cyclodextrin (CurA) and Kolliphor-ELP, Citrate (CurB). Cur formulations were more effective in prostate cancer (-19.54%) and less effective in gynecological non-breast cancers (0.30%). CurA showed better responses in samples of patients <40 (-13.81%) and >70 years of age (-17.74%). CurB had stronger effects in metastasized and heavily pretreated tumors. Combinations of Cur formulations and standard therapies were superior in 20/47 samples (42.55%) and inferior in 7/47 (14.89%). CurB stimulated chemo-doublets more strongly than monotherapies (-0.53% vs. -6.51%, p = 0.022) and more effectively than CurA (-6.51% vs. 3.33%, p = 0.005). Combinations of Cur formulations with Artesunate, Resveratrol and vitamin C were superior in 35/70 (50.00%) and inferior in 16/70 (22.86%) of samples. Cur formulations were significantly enhanced by combination with Artesunate (p = 0.020). Cur formulations showed a high variance in their anti-cancer effects, suggesting a need for individual testing before administration.